PR Newswire Clinical TrialsOriginal article
New Phase 3b data show Lilly's EBGLYSS (lebrikizumab-lbkz) delivered significant and rapid improvements in skin clearance, itch, pain, and patient satisfaction in people with moderate-to-severe hand and foot atopic dermatitis
Phase 3positiveEBGLYSSPositive
AI Analysis
Summary
Lilly's EBGLYSS (lebrikizumab-lbkz) achieved positive Phase 3b results in moderate-to-severe hand and foot atopic dermatitis, with >50% of patients reaching clear or almost clear skin by Week 16 and significant improvements in itch and pain.
Clinical Trial Data
Phase
3b
Primary Endpoint
Met
Outcome Details
Met primary endpoint with >50% of patients achieving clear or almost clear skin (HF-IGA 0/1) by Week 16; significant itch and pain relief demonstrated
Importance:7/10
Sentiment:
0.80
atopic dermatitisdermatologyPhase 3bmonotherapypositive data
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on September 30, 2026 12:03 PM